Last edition
News about "biopharmaceuticals"
Lupin Spins Out 2 Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
Lupin has spun off two oncology programs into Kaveri Therapeutics, retaining a significant equity stake while providing seed funding and exclusive program rights.
Biopharmaceuticals | 22/07/2026 | By News Bureau
India Poised to Become a Global Biopharma Leader: Anupriya Patel
Union Minister Anupriya Patel said India is well-positioned to become a global biopharma leader, highlighting the Biopharma SHAKTI initiative’s goal of launching 100 biologics by 2047. She urged the industry to strengthen capabilities in biologics and biosimilars.
Biopharmaceuticals | 12/06/2026 | By News Bureau | 137
Symbiosis Expands QC Capabilities with New Stability Chamber to Support Global Drug Supply
Symbiosis enhances its quality control lab with a new stability chamber, enabling comprehensive climate-based testing for global distribution of injectable drug products.
Biopharmaceuticals | 06/04/2026 | By News Bureau | 190
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
Biopharmaceuticals | 29/01/2026 | By News Bureau | 467
Samsung Biologics Inks Manufacturing Deal with Asian Pharmaceutical Company
With the latest agreement, the company's accumulated contract for 2024 surpasses USD 3.3 billion.
Biopharmaceuticals | 22/10/2024 | By Aishwarya | 672
Mankind Pharma to Acquire Bharat Serums and Vaccines
Mankind Pharma has signed a definitive agreement to acquire a 100 percent stake in Bharat Serums and Vaccines Ltd. (BSV) from Advent International, for an enterprise value of approx. INR 13,630 Crores, subject to closing-related adjustments.
Biopharmaceuticals | 26/07/2024 | By Aishwarya | 960
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy